Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PALA, amsacrine, teniposide, and zinostatin. Of the 66 evaluable patients, one partial response occurred among 17 patients treated with teniposide and no responses occurred with the other drugs. Two patients each treated with amsacrine and teniposide experienced life-threatening hematologic toxic effects and one patient treated with zinostatin died of thrombocytopenic pulmonary hemorrhage. The overall median patient survival was 9.6 weeks. Weight loss greater than or equal to 5% prior to therapy, extensive disease, and a nonambulatory status were associated with poor survival.
D000609:Aminoacridines / Q000009:adverse effects / Q000627:therapeutic use; D000677:Amsacrine; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D010746:Phosphonoacetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D011897:Random Allocation; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use; D009353:Zinostatin / Q000009:adverse effects / Q000627:therapeutic use
D000609:Aminoacridines; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000677:Amsacrine; D001224:Aspartic Acid; C013195:sparfosic acid; D009353:Zinostatin; D013713:Teniposide; D010746:Phosphonoacetic Acid